Effectiveness of Shakuyaku-kanzo-to in neuroleptic-induced hyperprolactinemia: A preliminary report

Kazuo Yamada, Shigenobu Kanba, Takaaki Murata, Motoko Fukuzawa, Bokusou Terashi, Gohei Yagi, Masahiro Asai

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

We investigated the efficacy of Shakuyaku-kanzo-to (TJ-68) in neuroleptic-induced hyperprolactinemia in 11 treated schizophrenic patients. The mean plasma prolactin level decreased significantly from 28.9 ± 14.5 ng/mL at baseline to 22.0 ± 15.2 ng/mL at 4 weeks. Potassium levels did not change significantly. Neither the exacerbation of psychosis nor other adverse effects occurred.

Original languageEnglish
Pages (from-to)341-342
Number of pages2
JournalPsychiatry and Clinical Neurosciences
Volume50
Issue number6
DOIs
Publication statusPublished - Jan 1 1996
Externally publishedYes

Fingerprint

Hyperprolactinemia
Antipsychotic Agents
Prolactin
Psychotic Disorders
Potassium
shakuyaku-kanzoh-toh

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Effectiveness of Shakuyaku-kanzo-to in neuroleptic-induced hyperprolactinemia : A preliminary report. / Yamada, Kazuo; Kanba, Shigenobu; Murata, Takaaki; Fukuzawa, Motoko; Terashi, Bokusou; Yagi, Gohei; Asai, Masahiro.

In: Psychiatry and Clinical Neurosciences, Vol. 50, No. 6, 01.01.1996, p. 341-342.

Research output: Contribution to journalArticle

Yamada, Kazuo ; Kanba, Shigenobu ; Murata, Takaaki ; Fukuzawa, Motoko ; Terashi, Bokusou ; Yagi, Gohei ; Asai, Masahiro. / Effectiveness of Shakuyaku-kanzo-to in neuroleptic-induced hyperprolactinemia : A preliminary report. In: Psychiatry and Clinical Neurosciences. 1996 ; Vol. 50, No. 6. pp. 341-342.
@article{c31367f39633470983b497ecfb09958d,
title = "Effectiveness of Shakuyaku-kanzo-to in neuroleptic-induced hyperprolactinemia: A preliminary report",
abstract = "We investigated the efficacy of Shakuyaku-kanzo-to (TJ-68) in neuroleptic-induced hyperprolactinemia in 11 treated schizophrenic patients. The mean plasma prolactin level decreased significantly from 28.9 ± 14.5 ng/mL at baseline to 22.0 ± 15.2 ng/mL at 4 weeks. Potassium levels did not change significantly. Neither the exacerbation of psychosis nor other adverse effects occurred.",
author = "Kazuo Yamada and Shigenobu Kanba and Takaaki Murata and Motoko Fukuzawa and Bokusou Terashi and Gohei Yagi and Masahiro Asai",
year = "1996",
month = "1",
day = "1",
doi = "10.1111/j.1440-1819.1996.tb00578.x",
language = "English",
volume = "50",
pages = "341--342",
journal = "Psychiatry and Clinical Neurosciences",
issn = "1323-1316",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Effectiveness of Shakuyaku-kanzo-to in neuroleptic-induced hyperprolactinemia

T2 - A preliminary report

AU - Yamada, Kazuo

AU - Kanba, Shigenobu

AU - Murata, Takaaki

AU - Fukuzawa, Motoko

AU - Terashi, Bokusou

AU - Yagi, Gohei

AU - Asai, Masahiro

PY - 1996/1/1

Y1 - 1996/1/1

N2 - We investigated the efficacy of Shakuyaku-kanzo-to (TJ-68) in neuroleptic-induced hyperprolactinemia in 11 treated schizophrenic patients. The mean plasma prolactin level decreased significantly from 28.9 ± 14.5 ng/mL at baseline to 22.0 ± 15.2 ng/mL at 4 weeks. Potassium levels did not change significantly. Neither the exacerbation of psychosis nor other adverse effects occurred.

AB - We investigated the efficacy of Shakuyaku-kanzo-to (TJ-68) in neuroleptic-induced hyperprolactinemia in 11 treated schizophrenic patients. The mean plasma prolactin level decreased significantly from 28.9 ± 14.5 ng/mL at baseline to 22.0 ± 15.2 ng/mL at 4 weeks. Potassium levels did not change significantly. Neither the exacerbation of psychosis nor other adverse effects occurred.

UR - http://www.scopus.com/inward/record.url?scp=0030459961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030459961&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1819.1996.tb00578.x

DO - 10.1111/j.1440-1819.1996.tb00578.x

M3 - Article

C2 - 9014235

AN - SCOPUS:0030459961

VL - 50

SP - 341

EP - 342

JO - Psychiatry and Clinical Neurosciences

JF - Psychiatry and Clinical Neurosciences

SN - 1323-1316

IS - 6

ER -